SG Americas Securities LLC trimmed its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Rating) by 47.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,802 shares of the biopharmaceutical company’s stock after selling 6,266 shares during the quarter. SG Americas Securities LLC’s holdings in Celldex Therapeutics were worth $303,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds have also bought and sold shares of the company. Wellington Management Group LLP boosted its holdings in shares of Celldex Therapeutics by 61.5% during the 1st quarter. Wellington Management Group LLP now owns 3,529,840 shares of the biopharmaceutical company’s stock valued at $120,227,000 after acquiring an additional 1,343,864 shares during the last quarter. Jennison Associates LLC bought a new stake in Celldex Therapeutics during the 3rd quarter worth approximately $35,813,000. Bellevue Group AG raised its position in shares of Celldex Therapeutics by 94.6% during the third quarter. Bellevue Group AG now owns 1,800,000 shares of the biopharmaceutical company’s stock valued at $50,598,000 after buying an additional 875,000 shares during the last quarter. Marshall Wace LLP raised its position in shares of Celldex Therapeutics by 3,159.9% during the third quarter. Marshall Wace LLP now owns 652,721 shares of the biopharmaceutical company’s stock valued at $18,348,000 after buying an additional 632,698 shares during the last quarter. Finally, State Street Corp increased its position in Celldex Therapeutics by 20.4% in the second quarter. State Street Corp now owns 3,228,852 shares of the biopharmaceutical company’s stock worth $87,050,000 after purchasing an additional 546,124 shares during the last quarter.
Celldex Therapeutics Stock Up 0.2 %
Shares of CLDX opened at $33.36 on Tuesday. The firm has a market cap of $1.58 billion, a P/E ratio of -13.24 and a beta of 2.10. The company has a current ratio of 17.07, a quick ratio of 17.07 and a debt-to-equity ratio of 0.01. The company’s 50-day moving average price is $36.84 and its 200 day moving average price is $39.25. Celldex Therapeutics, Inc. has a 12-month low of $19.85 and a 12-month high of $48.40.
Analyst Ratings Changes
Several research firms have commented on CLDX. StockNews.com began coverage on shares of Celldex Therapeutics in a research note on Thursday, March 16th. They set a “sell” rating for the company. HC Wainwright reaffirmed a “buy” rating and set a $73.00 price objective on shares of Celldex Therapeutics in a research note on Wednesday, March 1st. Finally, Cantor Fitzgerald dropped their price target on shares of Celldex Therapeutics from $55.00 to $54.00 in a research note on Friday.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379.
- Get a free copy of the StockNews.com research report on Celldex Therapeutics (CLDX)
- Is the Electric Vehicle Movement Losing Steam?
- 3 High-Yield Banks Insiders Are Buying
- Will ChatGPT Be the Final Nail in the Coffin for Chegg?
- Is the Market Reacting Too Negatively to Pinterest Earnings?
- More Analysts Should See Energizer Holdings As A Buy: Here Is Why
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.